Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation

Yuan Hung Kuo, Jing Houng Wang, Chao Hung Hung, Sheng Nan Lu, Tsung Hui Hu^*, Chien Hung Chen^*

^*此作品的通信作者